Evidence map›Paper›PMID 41751851›Full record

ArticleInternational journal of molecular sciences2026

Efficient

Vladimir Tolmachev, Amelinda Janice Herlina, Eleftherios Papalanis, Ekaterina A Bezverkhniaia, Eva Ryer, Anna Orlova, Fredrik Y Frejd, Maryam Oroujeni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0002-6122-1734
Amelinda Janice HerlinaDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Eleftherios PapalanisDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0009-0006-5340-8618
Ekaterina A BezverkhniaiaDepartment of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.ORCID 0000-0001-7699-5719
Eva RyerAffibody AB, 171 65 Solna, Sweden.
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.ORCID 0000-0001-6120-2683
Fredrik Y FrejdDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Maryam OroujeniDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-2660-9837

Funding

Swedish Cancer Society 23 2645 PjF 01HSwedish Cancer Society 243657 PjSwedish Cancer Society CAN 21 1485Swedish Research Council 2022-00556Swedish Research Council 2023-02158Swedish Society for Medical Research PG-22-0350-H-01
6 · The paper itself

Abstract

B7-H3 (CD276), an immune checkpoint protein, is overexpressed in malignant tumors, while its expression in normal tissues is low, and several B7-H3-targeting therapies are under clinical evaluation. Radionuclide molecular imaging offers a non-invasive method for determining B7-H3 expression levels and may aid in improved patient selection. The feasibility of the use of Affibody molecules for the visualization of B7-H3 was demonstrated earlier. The selection of an approach for routine labeling providing high radiochemical yields and reproducibility is, however, critical for successful clinical translation. The optimal combination of a targeting protein, chelator/linker, and radionuclide should provide high-contrast visualization. In this study, we evaluated an acyclic chelator, tris(3,4-hydroxypyridinone) (THP), for labeling of the Affibody molecule Z

Indexed as

B7 AntigensChelating AgentsGallium RadioisotopesPyridonesRadiopharmaceuticalsRecombinant Fusion ProteinsAnimalsCell Line, TumorFemaleHumansMiceTissue DistributionB7 AntigensCD276 protein, humanChelating AgentsGallium-68Gallium RadioisotopesPyridonesRadiopharmaceuticalsRecombinant Fusion ProteinsAffibody moleculeB7-H3gallium-68 (68Ga)NOTAPET imagingSKOV-3 xenograftTHP

Identifiers

PMID41751851
PMCPMC12941341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.